Durvalumab Market Report

Europe Durvalumab Market Size, Status and Forecast 2014-2026

  • POSTDATE：Dec 28, 2019
  • PAGES：210
  • REPORT CODE：GMM415482
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The Durvalumab market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 4.6% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Durvalumab Market Segmentations:

    By Player:

    • Medimmune (AstraZeneca)

    By Type:

    • 2.4mL Injection

    • 10mL Injection

    By End-User:

    • Locally Advanced Urothelial Carcinoma

    • Metastatic Urothelial Carcinoma

    • Other

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Durvalumab Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Durvalumab Market Size and Growth Rate of 2.4mL Injection from 2014 to 2026

    • 1.3.2 Europe Durvalumab Market Size and Growth Rate of 10mL Injection from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Durvalumab Market Size and Growth Rate of Locally Advanced Urothelial Carcinoma from 2014 to 2026

    • 1.4.2 Europe Durvalumab Market Size and Growth Rate of Metastatic Urothelial Carcinoma from 2014 to 2026

    • 1.4.3 Europe Durvalumab Market Size and Growth Rate of Other from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Durvalumab Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Durvalumab Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Durvalumab Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Durvalumab Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Durvalumab Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Durvalumab Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Durvalumab Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Durvalumab Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Durvalumab Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Durvalumab Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Durvalumab Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Durvalumab Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Durvalumab Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Durvalumab by Major Types

      • 3.4.1 Market Size and Growth Rate of 2.4mL Injection

      • 3.4.2 Market Size and Growth Rate of 10mL Injection

    4 Segmentation of Durvalumab Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Durvalumab by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Durvalumab for Locally Advanced Urothelial Carcinoma

      • 4.4.2 Market Size and Growth Rate of Durvalumab for Metastatic Urothelial Carcinoma

      • 4.4.3 Market Size and Growth Rate of Durvalumab for Other

    5 Market Analysis by Major Regions

    • 5.1 Europe Durvalumab Production Analysis by Top Regions

    • 5.2 Europe Durvalumab Consumption Analysis by Top Regions

    • 5.3 Europe Durvalumab Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Durvalumab Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Durvalumab Production, Import, Consumption and Export Analysis

      • 5.3.3 France Durvalumab Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Durvalumab Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Durvalumab Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Durvalumab Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Durvalumab Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Durvalumab Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Durvalumab Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Durvalumab Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Durvalumab Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Durvalumab Production, Import, Consumption and Export Analysis

    6 Product Circulation of Durvalumab Market among Top Countries

    • 6.1 Top 5 Export Countries in Durvalumab Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Durvalumab Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Durvalumab Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Durvalumab Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Durvalumab Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Durvalumab Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Durvalumab Landscape Analysis

    • 7.1 Germany Durvalumab Landscape Analysis by Major Types

    • 7.2 Germany Durvalumab Landscape Analysis by Major End-Users

    8. UK Durvalumab Landscape Analysis

    • 8.1 UK Durvalumab Landscape Analysis by Major Types

    • 8.2 UK Durvalumab Landscape Analysis by Major End-Users

    9. France Durvalumab Landscape Analysis

    • 9.1 France Durvalumab Landscape Analysis by Major Types

    • 9.2 France Durvalumab Landscape Analysis by Major End-Users

    10. Italy Durvalumab Landscape Analysis

    • 10.1 Italy Durvalumab Landscape Analysis by Major Types

    • 10.2 Italy Durvalumab Landscape Analysis by Major End-Users

    11. Spain Durvalumab Landscape Analysis

    • 11.1 Spain Durvalumab Landscape Analysis by Major Types

    • 11.2 Spain Durvalumab Landscape Analysis by Major End-Users

    12. Poland Durvalumab Landscape Analysis

    • 12.1 Poland Durvalumab Landscape Analysis by Major Types

    • 12.2 Poland Durvalumab Landscape Analysis by Major End-Users

    13. Russia Durvalumab Landscape Analysis

    • 13.1 Russia Durvalumab Landscape Analysis by Major Types

    • 13.2 Russia Durvalumab Landscape Analysis by Major End-Users

    14. Switzerland Durvalumab Landscape Analysis

    • 14.1 Switzerland Durvalumab Landscape Analysis by Major Types

    • 14.2 Switzerland Durvalumab Landscape Analysis by Major End-Users

    15. Turkey Durvalumab Landscape Analysis

    • 15.1 Turkey Durvalumab Landscape Analysis by Major Types

    • 15.2 Turkey Durvalumab Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Durvalumab Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Durvalumab Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Durvalumab Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Durvalumab Landscape Analysis by Top Countries

      • 16.3.1 Denmark Durvalumab Market Volume and Growth Rate

      • 16.3.2 Finland Durvalumab Market Volume and Growth Rate

      • 16.3.3 Norway Durvalumab Market Volume and Growth Rate

      • 16.3.4 Sweden Durvalumab Market Volume and Growth Rate

      • 16.3.6 Iceland Durvalumab Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Durvalumab Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Durvalumab Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Durvalumab Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Durvalumab Landscape Analysis by Top Countries

      • 17.3.1 Belgium Durvalumab Market Volume and Growth Rate

      • 17.3.2 Netherlands Durvalumab Market Volume and Growth Rate

      • 17.3.3 Luxembourg Durvalumab Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Durvalumab Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Durvalumab Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Durvalumab Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Durvalumab Landscape Analysis by Top Countries

      • 18.3.1 Estonia Durvalumab Market Volume and Growth Rate

      • 18.3.2 Latvia Durvalumab Market Volume and Growth Rate

      • 18.3.3 Lithuania Durvalumab Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Medimmune (AstraZeneca)

      • 19.1.1 Medimmune (AstraZeneca) Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    The List of Tables and Figures (Totals 84 Figures and 144 Tables)

    • Figure Product Picture

    • Figure Europe Durvalumab Market Size and Growth Rate of 2.4mL Injection from 2014 to 2026

    • Figure Europe Durvalumab Market Size and Growth Rate of 10mL Injection from 2014 to 2026

    • Figure Europe Durvalumab Market Size and Growth Rate of Locally Advanced Urothelial Carcinoma from 2014 to 2026

    • Figure Europe Durvalumab Market Size and Growth Rate of Metastatic Urothelial Carcinoma from 2014 to 2026

    • Figure Europe Durvalumab Market Size and Growth Rate of Other from 2014 to 2026

    • Figure Germany Durvalumab Market Size and Growth Rate from 2014 to 2026

    • Figure UK Durvalumab Market Size and Growth Rate from 2014 to 2026

    • Figure France Durvalumab Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Durvalumab Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Durvalumab Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Durvalumab Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Durvalumab Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Durvalumab Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Durvalumab Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Durvalumab Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Durvalumab Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Durvalumab Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Durvalumab Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Durvalumab Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Durvalumab Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Durvalumab Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Durvalumab Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Durvalumab Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Durvalumab Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Durvalumab Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Durvalumab Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Durvalumab Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Durvalumab Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Durvalumab Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Durvalumab Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Durvalumab Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Durvalumab

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Durvalumab by Different Types from 2014 to 2026

    • Table Consumption Share of Durvalumab by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of 2.4mL Injection

    • Figure Market Size and Growth Rate of 10mL Injection

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Durvalumab by Different End-Users from 2014 to 2026

    • Table Consumption Share of Durvalumab by Different End-Users from 2014 to 2026

    • Figure Market Size and Growth Rate of Locally Advanced Urothelial Carcinoma

    • Figure Market Size and Growth Rate of Metastatic Urothelial Carcinoma

    • Figure Market Size and Growth Rate of Other

    • Table Europe Durvalumab Production by Major Regions

    • Table Europe Durvalumab Production Share by Major Regions

    • Figure Europe Durvalumab Production Share by Major Countries and Regions in 2014

    • Table Europe Durvalumab Consumption by Major Regions

    • Table Europe Durvalumab Consumption Share by Major Regions

    • Table Germany Durvalumab Production, Import, Consumption and Export Analysis

    • Table UK Durvalumab Production, Import, Consumption and Export Analysis

    • Table France Durvalumab Production, Import, Consumption and Export Analysis

    • Table Italy Durvalumab Production, Import, Consumption and Export Analysis

    • Table Spain Durvalumab Production, Import, Consumption and Export Analysis

    • Table Poland Durvalumab Production, Import, Consumption and Export Analysis

    • Table Russia Durvalumab Production, Import, Consumption and Export Analysis

    • Table Switzerland Durvalumab Production, Import, Consumption and Export Analysis

    • Table Turkey Durvalumab Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Durvalumab Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Durvalumab Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Durvalumab Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Durvalumab Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Durvalumab Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Durvalumab Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Durvalumab Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Durvalumab Consumption by Types from 2014 to 2026

    • Table Germany Durvalumab Consumption Share by Types from 2014 to 2026

    • Table Germany Durvalumab Consumption by End-Users from 2014 to 2026

    • Table Germany Durvalumab Consumption Share by End-Users from 2014 to 2026

    • Table UK Durvalumab Consumption by Types from 2014 to 2026

    • Table UK Durvalumab Consumption Share by Types from 2014 to 2026

    • Table UK Durvalumab Consumption by End-Users from 2014 to 2026

    • Table UK Durvalumab Consumption Share by End-Users from 2014 to 2026

    • Table France Durvalumab Consumption by Types from 2014 to 2026

    • Table France Durvalumab Consumption Share by Types from 2014 to 2026

    • Table France Durvalumab Consumption by End-Users from 2014 to 2026

    • Table France Durvalumab Consumption Share by End-Users from 2014 to 2026

    • Table Italy Durvalumab Consumption by Types from 2014 to 2026

    • Table Italy Durvalumab Consumption Share by Types from 2014 to 2026

    • Table Italy Durvalumab Consumption by End-Users from 2014 to 2026

    • Table Italy Durvalumab Consumption Share by End-Users from 2014 to 2026

    • Table Spain Durvalumab Consumption by Types from 2014 to 2026

    • Table Spain Durvalumab Consumption Share by Types from 2014 to 2026

    • Table Spain Durvalumab Consumption by End-Users from 2014 to 2026

    • Table Spain Durvalumab Consumption Share by End-Users from 2014 to 2026

    • Table Poland Durvalumab Consumption by Types from 2014 to 2026

    • Table Poland Durvalumab Consumption Share by Types from 2014 to 2026

    • Table Poland Durvalumab Consumption by End-Users from 2014 to 2026

    • Table Poland Durvalumab Consumption Share by End-Users from 2014 to 2026

    • Table Russia Durvalumab Consumption by Types from 2014 to 2026

    • Table Russia Durvalumab Consumption Share by Types from 2014 to 2026

    • Table Russia Durvalumab Consumption by End-Users from 2014 to 2026

    • Table Russia Durvalumab Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Durvalumab Consumption by Types from 2014 to 2026

    • Table Switzerland Durvalumab Consumption Share by Types from 2014 to 2026

    • Table Switzerland Durvalumab Consumption by End-Users from 2014 to 2026

    • Table Switzerland Durvalumab Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Durvalumab Consumption by Types from 2014 to 2026

    • Table Turkey Durvalumab Consumption Share by Types from 2014 to 2026

    • Table Turkey Durvalumab Consumption by End-Users from 2014 to 2026

    • Table Turkey Durvalumab Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Durvalumab Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Durvalumab Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Durvalumab Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Durvalumab Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Durvalumab Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Durvalumab Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Durvalumab Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Durvalumab Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Durvalumab Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Durvalumab Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Durvalumab Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Durvalumab Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Durvalumab Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Durvalumab Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Durvalumab Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Durvalumab Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Durvalumab Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Durvalumab Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Durvalumab Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Durvalumab Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Durvalumab Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Durvalumab Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Durvalumab Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Durvalumab Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Durvalumab Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Durvalumab Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Durvalumab Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Durvalumab Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Durvalumab Market Volume and Growth Rate from 2014 to 2026

    • Table Company Profile and Development Status of Medimmune (AstraZeneca)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Medimmune (AstraZeneca)

    • Figure Sales and Growth Rate Analysis of Medimmune (AstraZeneca)

    • Figure Revenue and Market Share Analysis of Medimmune (AstraZeneca)

    • Table Product and Service Introduction of Medimmune (AstraZeneca)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US